Randomized trial shows empagliflozin significantly reduces inflammatory cells in women with prediabetes — Evidence Review

A new study finds that the diabetes drug empagliflozin can rapidly reduce inflammatory immune cell clusters linked to cardiovascular disease, suggesting a possible mechanism for its heart-protective effects. Related research generally supports the cardiovascular benefits of empagliflozin and other SGLT2 inhibitors, although the specific immune pathways involved were previously unclear; the new findings extend this knowledge by demonstrating direct immune modulation in humans (original study).

• Several large clinical trials have established that empagliflozin and similar SGLT2 inhibitors lower the risk of cardiovascular death and heart failure in type 2 diabetes patients, but prior studies mainly focused on metabolic or hemodynamic mechanisms rather than direct immune effects 3 4 5 9 11.
• Animal and in vitro studies suggest that empagliflozin may reduce inflammation and improve cardiac energy metabolism, but human evidence for immune modulation was lacking until now 2 7.
• The new study’s observation of rapid reductions in monocyte-platelet aggregates and metabolic reprogramming of immune cells provides a potential link between SGLT2 inhibition and decreased cardiovascular inflammation, expanding on prior hypotheses about empagliflozin’s protective mechanisms 1 6 7.

Study Overview and Key Findings

Despite strong evidence that SGLT2 inhibitors reduce cardiovascular events in people with type 2 diabetes, the biological mechanisms underlying these benefits have not been fully understood. Inflammation is increasingly recognized as a key contributor to cardiovascular disease, particularly in individuals with obesity and metabolic dysfunction. This study is notable for directly measuring changes in specific immune cell behaviors in humans after empagliflozin treatment, going beyond prior research that focused mainly on metabolic or hemodynamic endpoints.

The authors used advanced laboratory techniques to analyze immune cells and inflammatory markers in women with obesity and prediabetes, comparing empagliflozin treatment to a low-calorie diet over three months. The results suggest that empagliflozin rapidly decreases inflammatory cell clusters and shifts immune cell metabolism, which may underlie some of its cardiovascular benefits.

Property	Value
Organization	Vanderbilt Health
Journal Name	Circulation
Authors	B. Ilkin Safa, Jared M. Oakes, Joshua D. Simmons, Hui Nian, Leslie A. Kirk, Anna C. Cassidy, Eric C. Olson, Zaid Hatem, Christian M. Warren, Matthew S. Gonzalez, Taneem Amin, Quanhu Sheng, Anveetha Matta, Lyndon Zhu, Walid Hairan, Sara E. Howard, C. Robb Flynn, Matthew T. Stier, Erin M. Wilfong, Jeffrey C. Rathmell, Katherine N. Cahill, Jonathan D. Brown, Joshua A. Beckman, Curtis L. Gabriel, Jane E. Freedman, J. Matthew Luther, Samuel S. Bailin, Celestine N. Wanjalla, John R. Koethe, Spyros A. Kalams, Mona Mashayekhi
Population	Women with obesity and prediabetes
Sample Size	n=16
Methods	Randomized Controlled Trial (RCT)
Outcome	Inflammatory cell clusters, immune cell behavior
Results	MPA levels declined significantly within two weeks of starting empagliflozin

Literature Review: Related Studies

To place these findings in context, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant literature:

1. empagliflozin MPA levels diabetes
2. empagliflozin heart benefits mechanisms
3. diabetes drug cardiovascular outcomes

Below, we summarize the key themes and findings from related studies, organized by topic.

Topic	Key Findings
What mechanisms underlie the cardiovascular benefits of SGLT2 inhibitors?	- Empagliflozin appears to improve heart function by shifting myocardial energy metabolism from glucose to ketone bodies and free fatty acids, enhancing myocardial energetics and efficiency 4 6. - These drugs also exert diuretic effects, improving volume status in heart failure without causing significant electrolyte disturbances or neurohormonal activation 5.
Do SGLT2 inhibitors reduce cardiovascular inflammation in humans or animals?	- Animal and in vitro studies show empagliflozin reduces inflammation, activates AMPK, and favors anti-inflammatory immune cell profiles, but human evidence for direct immune modulation has been limited prior to the current study 2 7. - The new human study provides evidence of reduced inflammatory cell clusters (monocyte-platelet aggregates) and metabolic reprogramming of immune cells with SGLT2 inhibitor treatment, suggesting a potential anti-inflammatory mechanism 1.
What is the clinical impact of SGLT2 inhibitors on cardiovascular outcomes?	- Large clinical trials demonstrate that empagliflozin and other SGLT2 inhibitors reduce the risk of cardiovascular death, heart failure hospitalization, and all-cause mortality in type 2 diabetes, even beyond glycemic control 3 9 11. - Dapagliflozin, another SGLT2 inhibitor, also lowers the rate of cardiovascular death or hospitalization for heart failure, though not major adverse cardiovascular events (MACE) 11.
Are anti-inflammatory or metabolic effects unique to SGLT2 inhibitors among diabetes drugs?	- GLP-1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide) also reduce cardiovascular events in type 2 diabetes but act through different mechanisms, primarily affecting atherosclerotic events rather than heart failure 8 10 12. - SGLT2 inhibitors are distinct in their rapid onset of cardiovascular protection and effects on heart failure outcomes, possibly due to unique metabolic and immune pathways 3 9 11.

What mechanisms underlie the cardiovascular benefits of SGLT2 inhibitors?

Related studies suggest that empagliflozin’s cardiovascular benefits extend beyond blood sugar lowering, involving shifts in cardiac fuel metabolism and favorable diuretic effects. These mechanisms may improve myocardial energetics and reduce adverse cardiac remodeling. The new study’s demonstration of immune modulation introduces a potentially complementary pathway.

• Empagliflozin facilitates a shift in myocardial fuel use from glucose to ketone bodies and free fatty acids, increasing cardiac energetic efficiency 4 6.
• Improved blood volume and natriuresis are observed without the adverse effects associated with traditional diuretics 5.
• The rapid onset of cardiovascular benefits seen in large trials supports the involvement of mechanisms beyond glycemic or blood pressure control 3 6 9.
• The new study adds immune modulation to the list of potential protective mechanisms, suggesting a multifaceted benefit profile 1.

Do SGLT2 inhibitors reduce cardiovascular inflammation in humans or animals?

While animal and in vitro studies have demonstrated anti-inflammatory effects of empagliflozin, direct evidence in humans has been scarce. The current study addresses this gap by showing reductions in inflammatory monocyte-platelet aggregates and metabolic reprogramming of immune cells in humans.

• In vitro and animal studies report that empagliflozin reduces inflammatory cytokines and activates AMPK, promoting an anti-inflammatory immune environment 2 7.
• The shift from pro-inflammatory to more stable immune cell states may protect the heart from inflammation-related injury 7.
• Prior to this study, human data on direct immune cell changes with SGLT2 inhibitors were lacking 1.
• The observed reduction in monocyte-platelet aggregates in the new trial provides the first direct evidence of such effects in humans 1.

What is the clinical impact of SGLT2 inhibitors on cardiovascular outcomes?

Multiple large randomized trials have confirmed that SGLT2 inhibitors significantly lower the risk of cardiovascular and all-cause mortality in high-risk type 2 diabetes patients. These effects occur rapidly and appear to be independent of blood sugar control.

• Empagliflozin reduces risk of cardiovascular death, heart failure hospitalization, and all-cause mortality in patients with type 2 diabetes and high cardiovascular risk 3 9.
• Dapagliflozin also lowers rates of cardiovascular death or heart failure hospitalization, though not overall MACE 11.
• The benefits are observed early and are consistent across populations with and without established cardiovascular disease 3 9 11.
• The new study provides mechanistic insight that may help explain these rapid clinical effects 1.

Are anti-inflammatory or metabolic effects unique to SGLT2 inhibitors among diabetes drugs?

GLP-1 receptor agonists also reduce cardiovascular events but primarily affect atherosclerotic outcomes and do not show the same magnitude of benefit in heart failure as SGLT2 inhibitors. The distinct rapid cardioprotective effects of SGLT2 inhibitors may relate to their metabolic and immune-modulatory actions.

• Liraglutide, semaglutide, and dulaglutide lower risk of major adverse cardiovascular events, mainly by reducing atherosclerotic events 8 10 12.
• SGLT2 inhibitors uniquely reduce heart failure hospitalizations and may act through mechanisms involving metabolic shifts and inflammation reduction 3 9 11.
• The new findings provide evidence for an immune-related mechanism that sets SGLT2 inhibitors apart from other diabetes drugs 1.
• Understanding these differences could guide personalized therapy choices for patients with type 2 diabetes and differing cardiovascular risk profiles 8 10 12.

Future Research Questions

Although this study advances understanding of how SGLT2 inhibitors may protect the heart by modulating immune cell behavior, several important questions remain. Future research should address the durability of these immune changes, their relevance in broader populations, and how they interact with other known mechanisms of cardiovascular protection.

Research Question	Relevance
Do SGLT2 inhibitors reduce cardiovascular inflammation in diverse populations?	The current study focused on women with obesity and prediabetes; it is important to determine whether similar immune effects are seen in men, older adults, or patients with different metabolic profiles 1 9 11.
Are reductions in monocyte-platelet aggregates with SGLT2 inhibitors linked to clinical outcomes?	Establishing whether changes in immune cell clusters translate to reduced cardiovascular events or mortality will clarify the clinical significance of the observed immune modulation 1 3 9.
What is the duration and reversibility of immune changes with SGLT2 inhibitor therapy?	Understanding how long the immune changes persist and whether they reverse after stopping treatment will inform long-term management and potential risks or benefits of discontinuation 1 6.
How do SGLT2 inhibitors interact with other anti-diabetic drugs in modulating cardiovascular risk?	Since multiple drug classes (e.g., GLP-1 agonists, SGLT2 inhibitors) reduce cardiovascular events via different mechanisms, studies comparing or combining these agents may optimize therapy for high-risk patients 8 10 12.
What molecular pathways mediate immune reprogramming by SGLT2 inhibitors?	Elucidating the signaling and metabolic pathways that underlie immune cell shifts will enable development of targeted therapies and may identify new drug targets for cardiovascular disease prevention 2 6 7.